Company profile
XTL BIOPHARMACEUTICALS LTD
NASDAQ:XTLBBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BICIFADINE | phase2 | — | 2 | terminated, unknown |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00597649 | phase2 | terminated | 2007-10-01 | 2008-12-01 | XTL Biopharmaceuticals | A 52-Week Study of Bicifadine in Patients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy |
| NCT00553592 | phase2 | unknown | 2007-09-01 | — | XTL Biopharmaceuticals | Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes |
| NCT00300807 | phase1 | unknown | 2005-10-01 | — | XTL Biopharmaceuticals | Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection |
FDA applications (0)
No records yet.